12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
On January 16, 2020, the Department of Labor’s (DoL) Wage and Hour Division will publish a final ru...
Read More >
California Governor Gavin Newsom on Aug. 30 signed into law a bill that extends the deadline for sma...
Read More >
For several years, buyers and sellers in M&A deals have been turning to representations and warranti...
Read More >
On January 13, 2020, the Treasury Department-chaired inter-agency Committee on Foreign Investment in...
Read More >
Ever since the California Supreme Court issued its groundbreaking decision in Dynamex Operations W.,...
Read More >
This chart is intended to compare and contrast in summary form some of the considerations for a priv...
Read More >